Capricor Therapeutics (NASDAQ:CAPR) Given Buy Rating at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $77.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 450.28% from the company’s previous close.

Separately, Cantor Fitzgerald raised their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR traded up $0.32 during trading hours on Tuesday, hitting $13.99. 2,873,292 shares of the company were exchanged, compared to its average volume of 1,006,827. The firm has a fifty day simple moving average of $14.41 and a 200-day simple moving average of $13.87. The company has a market capitalization of $636.26 million, a PE ratio of -13.23 and a beta of 4.08. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Summit Investment Advisors Inc. grew its stake in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth about $78,000. Finally, New York State Common Retirement Fund grew its holdings in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.